Viewing Study NCT04100694


Ignite Creation Date: 2025-12-25 @ 1:44 AM
Ignite Modification Date: 2026-02-27 @ 10:39 AM
Study NCT ID: NCT04100694
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2025-05-20
First Post: 2019-09-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Sponsor: Merus N.V.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module